OncoMatch/Clinical Trials/NCT03952065
IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)
Is NCT03952065 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies PD1/PDL1/CTLA4 inhibitors for head/neck neoplasm.
Treatment: PD1/PDL1/CTLA4 inhibitors — This trial was designed to investigate the survival outcomes, response rates, and safety of patients with advanced Head/Neck Squamous cancer via intra-tumor or intra-artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: other clinical trials of equipment or drugs
Patients participated in other clinical trials of equipment or drugs (signed informed consent) within 4 weeks
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control; Platelet count < 60000/mm3, prothrombin activity < 50% [excluded]
Kidney function
Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]
Liver function
Total bilirubin < 51 μmol/L; Albumin > 28 g/L
Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L. Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%). Renal failure / insufficiency requiring hemo-or peritoneal dialysis. Known severe atheromatosis. Known uncontrolled blood hypertension (> 160/100 mm/Hg).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03952065 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior other clinical trials of equipment or drugs disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify